Noetic Fund
Toronto-based venture capital firm operating Fund I and Fund II, investing in early-stage psychedelic therapeutics, CNS drug discovery, digital health, and medical device companies addressing mental health. Founded in 2020-2021 by former DGAM/Carlyle executives.
- Company typePrivate
- Founded2021
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Noetic Fund does
Noetic Fund is a Toronto-based venture capital firm founded in 2020-2021 that invests in early-stage companies developing therapeutics and technologies for mental health and wellbeing. The firm operates two fund vehicles — Fund I and Fund II (the latter structured as a Cayman Islands limited partnership, "Noetic Fund II Cayman Master, LP") — and pursues a multi-modal thesis spanning novel CNS-targeted drug therapeutics, psychedelic-assisted therapies, digital health, medical devices and wearables. Its disclosed portfolio of 20+ companies includes psychedelic drug discovery platforms (CaaMTech, ASRI, Diamond Therapeutics, Gilgamesh Pharmaceutical, PsyBio Therapeutics, Psygen, Tactogen, Bexson Biomedical), therapy developers (Beckley Psytech, Delix Therapeutics, Eleusis, MindMed, COMPASS Pathways, Cybin), digital and device plays (Apollo Neuroscience, Merlyn Mind, Sana Health, Vessel, Wake) and evidence services (People Science, DAMONA Pharmaceuticals, Woven Science). Several portfolio holdings reached public markets (COMPASS Pathways NASDAQ:CMPS, Cybin NYSE:CYBN/NEO:CYBN, MindMed NASDAQ:MNMD, Numinus TSXV:NUMI, Eleusis) with Noetic marking each as exited.
The firm is led by Managing Partners Sa'ad Shah and Warren Wright — both former senior executives at DGAM (acquired by The Carlyle Group), where Sa'ad served as Head of Marketing and Client Services helping build AUM to $6.8B at peak, and Warren as Chief Investment Officer and subsequently Partner/CIO of The Carlyle Liquid Markets Group. The investment team is rounded out by Principal & Scientific Lead Sri Teja Mullapudi, Ph.D. (Max Planck, summa cum laude), General Counsel Richard Cheung (licensed pharmacist and Canadian patent/trademark agent), Principal of Finance & Operations Yee Tan, Head of Real World Evidence Victor Mifsud, and clinical advisors Jeffrey Becker, MD and Marine Mallinson.
Noetic generates economics in the conventional VC manner — through management fees on committed capital from limited partners and, ultimately, carried interest and capital gains from portfolio exits. The firm does not develop proprietary technology products; instead, it competes on differentiated deal flow, sector specialization, and value-add support, evidenced by proprietary content properties such as the "Sessions of Intellectual Discovery" video series and Sa'ad's Reading List that double as founder-sourcing channels. Disclosed check sizes include $6.95M (ASRI lead), the majority of $22M (CaaMTech Series A lead), and $5.5M (DAMONA). No public AUM, fund size, or revenue figures are disclosed.
Noetic Fund firmographics
Firmographics- Name
- Noetic Fund
- Legal name
- Noetic Fund
- Website
- https://noeticfund.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Toronto-based venture capital firm operating Fund I and Fund II, investing in early-stage psychedelic therapeutics, CNS drug discovery, digital health, and medical device companies addressing mental health. Founded in 2020-2021 by former DGAM/Carlyle executives.
- Ownership category
- akta.pro rank
Noetic Fund industry classification
Industry- Product category
- Venture Capital
- NAICS
- Scientific Research and Development Services (5417), Open-End Investment Funds (525910)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Independent Venture Debt Funds / Platforms (FSANAIAB)
- akta.pro secondary industry
- Large-Cap / Sponsor Finance Direct Lending (FSANADAJ)
Keywords
Where Noetic Fund is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Noetic Fund business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Venture Capital Returns: As a venture capital fund, Noetic generates returns through carried interest and investment gains from portfolio companies. They invest capital from limited partners into early-stage companies with potential for significant value appreciation in the mental health and psychedelic therapeutics sectors.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Noetic Fund product offering
Product offeringCore offering
Noetic Fund is a Toronto-based venture capital firm operating two investment funds (Fund I and Fund II) that deploy capital into early-stage companies developing CNS-targeted therapeutics and related mental health solutions. The firm pursues a diversified, multi-modal investment strategy spanning novel drug therapeutics, psychedelic-assisted therapies, digital health, medical devices, and wearables, targeting treatments that address root causes of illness with emphasis on early intervention and prevention.
Product overview
Noetic Fund is a venture capital firm (not a technology product company) that operates two investment funds: Fund I and Fund II. The firm invests in early-stage mental health technologies across multiple modalities including novel drug therapeutics, psychedelic-assisted therapies, digital health, medical devices, and wearables. Beyond its investment funds, Noetic offers educational content through its Sessions of Intellectual Discovery video series featuring expert discussions on mental health research and psychedelic medicine, and maintains a curated reading list of relevant literature compiled by its team.
Differentiator
Problem solved
Functional benefit
Brands
- Noetic Fund II: The second investment fund vehicle managed by Noetic Fund.
- Sessions of Intellectual Discovery
Products and services
- Noetic Fund I Noetic Fund's first investment vehicle offering limited partners exposure to a portfolio of early-stage companies developing CNS-targeted therapeutics, psychedelic-assisted therapies, digital health, medical devices, and wearables addressing mental health and physical wellbeing.
- Noetic Fund II Noetic Fund's second investment vehicle structured as a Cayman Islands limited partnership, continuing to invest in early-stage mental health and CNS-targeted therapeutic companies with a global outlook and multi-modal strategy.
Companies that use Noetic Fund
Customer profileSegments1 record
Ideal customer profiles2 records
Noetic Fund technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Noetic Fund partnerships and signals
Strategic signalScale indicators6 records
Recent moves6 records
Expansion highlights5 records
Noetic Fund competitors and assessment
Company assessmentDirect peers
- Neo Kuma Ventures: Neo Kuma is a thesis-driven venture fund backing psychedelic and mental-health startups, often as lead or co-lead investor. Closely matches Noetic's psychedelic-focused, early-stage mandate.
- Bail Capital: Bail Capital is a venture firm investing in psychedelic and cannabis-adjacent technology and life-sciences companies. Overlaps with Noetic on early-stage, sector-thematic mandate.
- Palo Santo Ventures: Palo Santo is a dedicated psychedelic-medicine venture fund that invests in early-stage companies developing psychedelic therapeutics and related mental-health infrastructure. Most directly comparable to Noetic in mandate, stage focus, and sector concentration.
- JLS Fund: JLS Fund (formerly JLS Investments) is a single-LP vehicle dedicated to psychedelic medicine investing. Comparable in scale, structure, and sector concentration to Noetic.
- Empath Ventures: Empath Ventures is a psychedelic-medicine venture fund backing companies developing novel mental-health therapeutics. Closely comparable to Noetic on thesis and stage focus.
- Iter Investments: Iter is an early-stage investor focused on psychedelic and cannabis medicine companies, including drug discovery and therapy-delivery platforms. Highly comparable to Noetic on stage, sector, and check size.
- Salvia Ventures: Salvia Ventures is a single-theme fund investing in psychedelic medicine companies from preclinical to commercial stages. Directly comparable to Noetic on fund structure and sector focus.
Broad incumbents
- Lux Capital: Lux Capital is a science- and technology-focused venture firm that has backed frontier neurotech and mental-health companies. Comparable to Noetic on frontier-science orientation rather than on psychedelic specificity.
- Founders Fund: Founders Fund, through Peter Thiel's public advocacy, has been one of the most prominent generalist VCs with material psychedelic-medicine exposure (e.g., earlier backing of Compass-adjacent theses). Broader mandate but overlapping psychedelic deal flow.
Others
- Woven Science: Woven Science is a holding/investment platform creating and supporting early-stage psychedelic and wellness companies, overlapping with several of Noetic's portfolio names. Indirect competitor/ecosystem participant rather than a direct fund peer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Noetic Fund social profiles
Digital presenceNoetic Fund financial estimates
Financial estimateRevenue estimate
Valuation estimate
Noetic Fund leadership team
Management profileNumber of profiles
Profiles9 records
Noetic Fund funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Noetic Fund M&A and investment
M&A and investmentM&A
Investments25 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Noetic Fund
What does Noetic Fund do?
Noetic Fund is a Toronto-based venture capital firm operating two investment funds (Fund I and Fund II) that deploy capital into early-stage companies developing CNS-targeted therapeutics and related mental health solutions. The firm pursues a diversified, multi-modal investment strategy spanning novel drug therapeutics, psychedelic-assisted therapies, digital health, medical devices, and wearables, targeting treatments that address root causes of illness with emphasis on early intervention and prevention.
Is Noetic Fund a public or private company?
Noetic Fund is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Noetic Fund founded?
Noetic Fund was founded in 2021. It employs 11 to 50 people.
Where is Noetic Fund based?
Noetic Fund is headquartered in Toronto, Canada, in the North America region.
How does Noetic Fund make money?
One revenue line is on record: venture Capital Returns.
Who are Noetic Fund's main competitors?
Direct peers on record are Neo Kuma Ventures, Bail Capital, Palo Santo Ventures, JLS Fund, Empath Ventures, Iter Investments and Salvia Ventures. Broad incumbents are Lux Capital and Founders Fund. Woven Science is listed as an others.
Does Noetic Fund have an API?
No public API is recorded for Noetic Fund.
What industry is Noetic Fund in?
Noetic Fund's product category is Venture Capital. Its primary akta.pro industry code is FSANAIAB, Independent Venture Debt Funds / Platforms, with a secondary code of FSANADAJ, Large-Cap / Sponsor Finance Direct Lending. Its NAICS code is 5417 and its SIC code is 6282.